Other antidiabetic drug classes have previously been profiled in db/db UNx-ReninAAV mice, including rosiglitazone (peroxisome proliferator-activated receptor-γ agonist) and empagliflozin (SGLT2 inhibitor), which robustly reduces hyperglycemia, without, however, influencing hypertension and kidney histopathology in the model [13,14,31]. This evidence concerns the gene SLC5A2 and Hyperglycemia.